製品番号: HY-N6017

Bakkenolide A

カスタマーレビュー

Based on 1 Customer Validation

Bakkenolide A is an anticancer agent. Bakkenolide A reduces the viability of leukemia cells, inhibits cell colony formation and invasion, and downregulates the expression of HDAC3 in cells. Bakkenolide A downregulates the expression of pro-inflammatory cytokines including TNF-α, interleukins such as IL-1β, TGF-β1 and IFN-γ, as well as the expression of PI3K, PDK and PKC in leukemia cells. Bakkenolide A downregulates activated Akt, GSK and Bad, while upregulates Cyto-c, cleaved Caspase3 and cleaved Caspase7, induces apoptosis (apoptosis) in leukemia cells and thereby inhibits inflammatory responses in leukemia cells. Bakkenolide A significantly slows the growth of subcutaneous leukemia tumors in nude mice. Bakkenolide A is applicable to leukemia-related research.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.99%
CAS 番号: 19906-72-0
分子式: C₁₅H₂₂O₂
分子量:234.33

保管条件:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Bakkenolide A 構造式

CAS 番号: 19906-72-0

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性

製品説明

HDAC アイソフォーム固有の製品をすべて表示 :

TNF Receptor アイソフォーム固有の製品をすべて表示 :

Interleukin Related アイソフォーム固有の製品をすべて表示 :

TGF-β Receptor アイソフォーム固有の製品をすべて表示 :

PI3K アイソフォーム固有の製品をすべて表示 :

PKC アイソフォーム固有の製品をすべて表示 :

Akt アイソフォーム固有の製品をすべて表示 :

GSK-3 アイソフォーム固有の製品をすべて表示 :

Caspase アイソフォーム固有の製品をすべて表示 :

体外実験

Bakkenolide A (50-250 μM; 8-80 h) reduces the viability of human leukemia K562 cells, inhibits cell colony formation and invasion, and downregulates the mRNA and protein expression of HDAC3 in cells^[1].
Bakkenolide A (200 μM; 48 h) significantly downregulates the expression of proinflammatory cytokines TNF-α, IL-1β, IL-18, IL-6, IL-8, IL-2, TGF-β1, IFN-γ and IL-17, as well as the expression of PI3K, PDK and PKC, in human leukemia K562 cells^[1].
Bakkenolide A (200 μM; 48 h) induces apoptosis in human leukemia K562 cells by downregulating activated Akt, GSK and Bad, while upregulating cytochrome c (Cyto-c), cleaved Caspase3 and cleaved Caspase7^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

human leukemia K562 cells
Concentration:

50, 100,
150, 200 and 250 mM (48 h viability assay); 200 μM (time-dependent viability assay)
Incubation Time:

48 h (50, 100, 150, 250 μM); 8, 16, 24, 32, 40, 48, 56, 64, 72 and 80 h (200 μM)
Result:

Reduced K562 cell viability in a time-dependent manner at 200 μM, with significant inhibition observed at 48 h and later time points.
Reduced K562 cell viability at 50, 100, 150, 200, and 250 μM for 48 h, with the most stable and effective inhibition seen at 200 μM.

RT-PCR^[1]

Cell Line:

human leukemia K562 cells
Concentration:

200 μM
Incubation Time:

48 h
Result:

Significantly reduced HDAC3 mRNA expression in K562 cells to levels similar to those seen in HDAC3-knockdown K562 cells.

Cell Invasion Assay^[1]

Cell Line:

human leukemia K562 cells
Concentration:

200 μM
Incubation Time:

48 h
Result:

Significantly reduced the invasive capacity of K562 cells, with relative invasion rates reduced to levels similar to those seen in HDAC3-knockdown K562 cells.

Western Blot Analysis^[1]

Cell Line:

human leukemia K562 cells
Concentration:

200 μM
Incubation Time:

48 h
Result:

Significantly reduced protein expression of TNF-α, IL-1β, and IL-18 in K562 cells.

Immunofluorescence^[1]

Cell Line:

human leukemia K562 cells
Concentration:

200 μM
Incubation Time:

48 h
Result:

Significantly reduced PI3K expression in K562 cells.

Apoptosis Analysis^[1]

Cell Line:

human leukemia K562 cells
Concentration:

200 μM
Incubation Time:

48 h
Result:

Significantly accelerated apoptosis in K562 cells via flow cytometry.
Reduced activated (phosphorylated) Akt, GSK, and Bad protein expression in K562 cells.
Increased Cyto-c, cleaved Caspase3, and cleaved Caspase7 protein expression in K562 cells.

体内実験

Bakkenolide A (200 μM pre-treatment of K562 cells, s.c., single administration) significantly slows the growth of subcutaneous leukemia tumors in Balb/c nude mice, reduces the expression level of HDAC3 in tumor tissues, increases the level of Caspase3, and decreases the final tumor weight after mice are sacrificed^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Balb/c nude mice^[1]
Dosage:

200 μM pre-treatment of K562 cells (5 x 10⁶ per mouse)
Administration:

s.c., single administration
Result:

Significantly slowed the growth of subcutaneous leukemia tumors in Balb/c nude mice, reduced HDAC3 expression levels in tumor tissues, increased caspase3 levels, and decreased the final tumor weight of mice after sacrifice.

化学情報

CAS 番号 19906-72-0
性状 Solid
分子量 234.33
分子式 C₁₅H₂₂O₂
Color White to off-white
SMILES

O=C([C@@]12C[C@@]3([H])CCC[C@H](C)[C@@]3(C)C2)OCC1=C
Structure Classification
- Terpenoids
- Sesquiterpenes
Initial Source
輸送条件

Room temperature in continental US; may vary elsewhere.
保管条件

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

溶剤 & 溶解度

体外:

DMSO : 50 mg/mL (213.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.2675 mL

21.3374 mL

42.6749 mL

5 mM

0.8535 mL

4.2675 mL

8.5350 mL

10 mM

0.4267 mL

2.1337 mL

4.2675 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (5.33 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (5.33 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (5.33 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (286 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Zhang L, et al. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways. Biomed Pharmacother. 2016;83:958-966. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.2675 mL	21.3374 mL	42.6749 mL	106.6871 mL
	5 mM	0.8535 mL	4.2675 mL	8.5350 mL	21.3374 mL
	10 mM	0.4267 mL	2.1337 mL	4.2675 mL	10.6687 mL
	15 mM	0.2845 mL	1.4225 mL	2.8450 mL	7.1125 mL
	20 mM	0.2134 mL	1.0669 mL	2.1337 mL	5.3344 mL
	25 mM	0.1707 mL	0.8535 mL	1.7070 mL	4.2675 mL
	30 mM	0.1422 mL	0.7112 mL	1.4225 mL	3.5562 mL
	40 mM	0.1067 mL	0.5334 mL	1.0669 mL	2.6672 mL
	50 mM	0.0853 mL	0.4267 mL	0.8535 mL	2.1337 mL
	60 mM	0.0711 mL	0.3556 mL	0.7112 mL	1.7781 mL
	80 mM	0.0533 mL	0.2667 mL	0.5334 mL	1.3336 mL
	100 mM	0.0427 mL	0.2134 mL	0.4267 mL	1.0669 mL

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Bakkenolide A

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

TGF-beta/Smad Compound Library

Wnt/Hedgehog/Notch Compound Library

Natural Product Library

Histone Modification Research Compound Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Alzheimer's Disease Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Tibetan Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mongolian Medicine Compound Library

High-Efficiency Gene Editing Compound Library

Natural Product Diversity Scaffold Library